Filtered By:
Drug: Dexamethasone
Education: Academia
This page shows you your search results in order of date.
Order by Relevance | Date
Total 29 results found since Jan 2013.
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
CONCLUSION: In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.PMID:37543510 | DOI:10.1016/j.clml.2023.07.009
Source: Clinical Lymphoma and Myeloma - August 5, 2023 Category: Cancer & Oncology Authors: Alexa J Loncharich Mark A Fiala Michael J Slade Angela Vickroy Margaret Kavanaugh Carmen Wilson Mark A Schroeder Keith Stockerl-Goldstein Ravi Vij Kristen M Sanfilippo Source Type: research
How do we …consistently provide high-dose granulocyte products for transfusions in neutropenic patients?
This study demonstrates that the combination of G-CSF and dexamethasone donor stimulation, followed by apheresis granulocyte collection, is safe and can reliably yield a high-dose product. Consistent production of high-dose units allows for better assessment of patient outcomes by reducing dosage variability.PMID:37358345 | DOI:10.1111/trf.17461
Source: Transfusion - June 26, 2023 Category: Hematology Authors: Robert Bubar Joseph E Kiss Darrell J Triulzi Pam D'Andrea Ashley Zilich Alesia Kaplan Source Type: research
Systemic Effects of Perineural Glucocorticoids on Fasting Serum Glucose, Potassium, and White Blood Cell Count in Total Hip Arthroplasty
CONCLUSION: Patients who underwent THA and received PAI+PNB with glucocorticoid adjuvants demonstrated higher elevations in serum glucose for the first two PODs compared to patients who received PAI alone. These differences resolved by a third POD and are likely to be of no clinical significance.PMID:36846205 | PMC:PMC9946012 | DOI:10.2147/JPR.S395336
Source: Cell Research - February 27, 2023 Category: Cytology Authors: Avijit Sharma Feng Dai Lanya Tseng Philip R Effraim Bin Zhou Robert B Schonberger Jinlei Li Source Type: research
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
This study is an interim analysis of ATLAS, which is an investigator-initiated, multicentre, open-label, randomised, phase 3 trial in 12 academic and clinical centres in the USA and Poland. Participants were aged 18 years or older with newly diagnosed multiple myeloma, completed any type of induction and had stable disease or better, autologous stem-cell transplantation within 100 days, initiated induction 12 months before enrolment, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) using permuted blocks of sizes 4 and 6 and a web-based system to receive up to 36 ...
Source: Ann Oncol - January 15, 2023 Category: Cancer & Oncology Authors: Dominik Dytfeld Tomasz Wr óbel Krzysztof Jamroziak Tadeusz Kubicki Pawe ł Robak Adam Walter-Croneck Jaros ław Czyż Agata Tyczy ńska Agnieszka Druzd-Sitek Krzysztof Giannopoulos Adam Nowicki Tomasz Szczepaniak Anna Łojko-Dankowska Magdalena Matuszak Source Type: research
Antenatal corticosteroids prior to planned caesarean at term for improving neonatal outcomes
CONCLUSIONS: Evidence from one randomised controlled trial suggests that prophylactic corticosteroids before elective caesarean section at term probably reduces admission to the neonatal intensive care unit for respiratory morbidity. It is uncertain if administration of antenatal corticosteroids reduces the rates of respiratory distress syndrome (RDS) or transient tachypnoea of the neonate (TTN). The overall certainty of the evidence for the primary outcomes was found to be low or very low, apart from the outcome of admission to neonatal special care (all levels) for respiratory morbidity, for which the evidence was of mod...
Source: Cochrane Database of Systematic Reviews - December 22, 2021 Category: General Medicine Authors: Alexandros Sotiriadis Emma McGoldrick George Makrydimas Stefania Papatheodorou John Pa Ioannidis Fiona Stewart Roses Parker Source Type: research
Late ( ≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
CONCLUSIONS: Late systemic postnatal corticosteroid treatment (started at seven days or more after birth) reduces the risks of mortality and BPD, and the combined outcome of mortality or BPD, without evidence of increased cerebral palsy. However, the methodological quality of studies determining long-term outcomes is limited, and no studies were powered to detect increased rates of important adverse long-term neurodevelopmental outcomes. This review supports the use of late systemic corticosteroids for infants who cannot be weaned from mechanical ventilation. The role of late systemic corticosteroids for infants who are no...
Source: Cochrane Database of Systematic Reviews - November 10, 2021 Category: General Medicine Authors: Lex W Doyle Jeanie L Cheong Susanne Hay Brett J Manley Henry L Halliday Source Type: research
Early ( & amp;lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
CONCLUSIONS: Early systemic postnatal corticosteroid treatment (started during the first six days after birth) prevents BPD and the combined outcome of mortality or BPD. However, it increases risks of gastrointestinal perforation, cerebral palsy, and the combined outcome of mortality or cerebral palsy. Most beneficial and harmful effects are related to early treatment with dexamethasone, rather than to early treatment with hydrocortisone, but early hydrocortisone may prevent mortality, whereas early dexamethasone does not. Longer-term follow-up into late childhood is vital for assessment of important outcomes that cannot b...
Source: Cochrane Database of Systematic Reviews - October 21, 2021 Category: General Medicine Authors: Lex W Doyle Jeanie L Cheong Susanne Hay Brett J Manley Henry L Halliday Source Type: research
Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study
CONCLUSION: Dexamethasone, an evidence-based treatment of COVID-19, may be underused among persons who are mechanically ventilated. The use of remdesivir and dexamethasone varied across health systems, suggesting variation in patient case mix, drug access, treatment protocols, and quality of care.PRIMARY FUNDING SOURCE: National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; and National Institute on Aging.PMID:34399060 | DOI:10.7326/M21-0857
Source: Annals of Internal Medicine - August 16, 2021 Category: Internal Medicine Authors: Hemalkumar B Mehta Huijun An Kathleen M Andersen Omar Mansour Vithal Madhira Emaan S Rashidi Benjamin Bates Soko Setoguchi Corey Joseph Paul T Kocis Richard Moffitt Tellen D Bennett Christopher G Chute Brian T Garibaldi G Caleb Alexander National COVID Co Source Type: research
